Company profile
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions.
- CEO
- Dr. Lawrence Otto Klein Ph.D.
- Headquarters
- Menlo Park, CA, United States
- Employees
- 68
- IPO date
- Aug 8, 1997
- Sector
- Healthcare
- Industry
- Biotechnology